Category: 655225-01-7

655225-01-7, tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 1: To a solution of la in DMF was added NaH with ice-bath. The resulting mixture was stirred for 15min. at 0-5 °C and was added lb. The reaction mixture was stirred at r.t. for 2h and evaporated to remove DMF. The residue was purified by column chromatography (PE:EA=8:1) to give lc (1.74g, 67.4percent).

655225-01-7, The synthetic route of 655225-01-7 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; TYROGENEX, INC.; LIANG, Congxin; WO2011/41399; (2011); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

655225-01-7,655225-01-7, tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 2-(5-chloro-2,4-dimethoxyphenyl)-7-(piperazin-1-yl)imidazo[1,2-a]pyridme 12 (200 mg, 0.50 mmol), tert-butyl 4-(2-bromoethyl)piperazine-1-carboxylate (160 mg, 0.53 mmol), and potassium carbonate ( 140 mg, 1.00 mmol) in acetonitriie (4 mL) was heated to reflux for 3 h. The reaction mixture was filtered and the filtrate was distilled under reduced pressure. The residue was purified by combi-flash chromatography (silica gel, 9: 1 DCM/MeOH) to afford tert-butyl 4-(2-(4-(2-(5-chloro-2,4- dimethoxyphenyl)imidazo[1 2-a]-pyridin-7-yl)piperazin-1-yl)ethyl)piperazine-1-carboxylate 13k (130 mg, 42percent) as a pale yellow solid. 1H NMR (400 MHz, CDCl3): delta 8.38 (s, 1H), 7.88 (d, J= 7.6 Hz, 1H), 7.86 (s, 1H). 6.80 (d, J= 7.5 Hz, 1H), 6.57 (s, 1H), 6.55 (dd, J=2.3, 7.6 Hz, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.44 (t, J= 5.1 Hz, 4H), 3.24 (t, J= 5.1 Hz, 4H), 2.66 (t, J= 5.0 Hz, 4H), 2.61-2.54 (m, 4H), 2.44 (t, J= 5.0 Hz, 4H), 1.46 (s, 9H); HPLC ( Method 1) 99.0percent (AUC), tR = 9.55 min. ; ESI MS m/z 585 [M + H]+.

As the paragraph descriping shows that 655225-01-7 is playing an increasingly important role.

Reference：
Patent; ONCOTHERAPY SCIENCE, INC.; MATSUO, Yo; HISADA, Shoji; NAKAMURA, Yusuke; CHAKRABARTI, Anjan; RAWAT, Manish; RAI, Sanjay; SATYANARAYANA, Arvapalli, Venkata; DUAN, Zhiyong; TALUKDAR, Arindam; RAVULA, Srinivas; DECORNEZ, Helene; (491 pag.)WO2017/58503; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

655225-01-7,655225-01-7, tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 2-(5-chloro-2,4-dimethoxyphenyl)-7-(piperazin-1-yl)imidazo[1,2-a]pyridme 12 (200 mg, 0.50 mmol), tert-butyl 4-(2-bromoethyl)piperazine-1-carboxylate (160 mg, 0.53 mmol), and potassium carbonate ( 140 mg, 1.00 mmol) in acetonitriie (4 mL) was heated to reflux for 3 h. The reaction mixture was filtered and the filtrate was distilled under reduced pressure. The residue was purified by combi-flash chromatography (silica gel, 9: 1 DCM/MeOH) to afford tert-butyl 4-(2-(4-(2-(5-chloro-2,4- dimethoxyphenyl)imidazo[1 2-a]-pyridin-7-yl)piperazin-1-yl)ethyl)piperazine-1-carboxylate 13k (130 mg, 42percent) as a pale yellow solid. 1H NMR (400 MHz, CDCl3): delta 8.38 (s, 1H), 7.88 (d, J= 7.6 Hz, 1H), 7.86 (s, 1H). 6.80 (d, J= 7.5 Hz, 1H), 6.57 (s, 1H), 6.55 (dd, J=2.3, 7.6 Hz, 1H), 3.99 (s, 3H), 3.95 (s, 3H), 3.44 (t, J= 5.1 Hz, 4H), 3.24 (t, J= 5.1 Hz, 4H), 2.66 (t, J= 5.0 Hz, 4H), 2.61-2.54 (m, 4H), 2.44 (t, J= 5.0 Hz, 4H), 1.46 (s, 9H); HPLC ( Method 1) 99.0percent (AUC), tR = 9.55 min. ; ESI MS m/z 585 [M + H]+.

As the paragraph descriping shows that 655225-01-7 is playing an increasingly important role.

Reference：
Patent; ONCOTHERAPY SCIENCE, INC.; MATSUO, Yo; HISADA, Shoji; NAKAMURA, Yusuke; CHAKRABARTI, Anjan; RAWAT, Manish; RAI, Sanjay; SATYANARAYANA, Arvapalli, Venkata; DUAN, Zhiyong; TALUKDAR, Arindam; RAVULA, Srinivas; DECORNEZ, Helene; (491 pag.)WO2017/58503; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

655225-01-7,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

The compound obtained in Example 35-2 (74 mg, 0.55 mmol) was dissolved in DMF (1.5 ml). There to cesium carbonate (214 mg, 0.66 mmol), tertiaryButyl 4- (2-bromomethyl) piperazine-1-Carboxylate(323 mg, 1.1 mmol), potassium iodide (183 mg, 1.1 mmol) and stirred overnight at 70 ° C. was added a. After the reaction, the solvent was evaporated. The residue was purified by silica gel column chromatography (Chromatorex NH 20 g, hexane / ethyl acetate) to give the title compound (184 mg, 96.3percent) as a yellow oil.

655225-01-7 tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate 15946441, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; Yakult Honsha Co., Ltd.; University of Occupational and Environmental Health; Ono, Masahiro; Kobayashi, Tsuneyuki; Yamazaki, Ryuta; Haibara, Hirotake; Nishiyama, Yukiko; Hokkyo, Atsuko; Nishiyama, Hiroyuki; Kurita, Akinobu; Matsuzaki, Ken; Kono, Kimitoshi; Izumi, Hiroto; (215 pag.)JP2016/124812; (2016); A;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

655225-01-7, Preparation 7.3N-Methyl-N-[2-(piperazin-1 -yl)ethyl]acetamide ditrifluoroacetate. 0.341 g of 60percent NaH in oil is added to a solution of 0.748 g of N- methylacetamide in 80 ml of THF and stirred for 10 minutes at RT. Then 2 g of fe/f-butyl 4-(2-bromoethyl)piperazinecarboxylate is added and stirred for 16 hours at RT. Water is added to the reaction mixture, it is decanted and the organic solvent is evaporated under vacuum. The residue is dissolved in DCM, filtered through a Chem Elut.(R). cartridge, eluting with DCM and the solvents are evaporated under vacuum. The residue is purified by preparative HPLC and a white solid is obtained. The solid is dissolved in 5 ml of DCM, 1 .2 ml of TFA is added and it is stirred for 16 hours at RT. The reaction mixture is diluted by adding 100 ml of toluene and the solvents are concentrated under vacuum.1 .5 g of the expected compound is obtained.

The synthetic route of 655225-01-7 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; SANOFI; BADORC, Alain; BOLDRON, Christophe; DELESQUE, Nathalie; FOSSEY, Valerie; LASSALLE, Gilbert; YVON, Xavier; WO2012/146318; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

655225-01-7, STEP A: Sodium hydride (60percent mineral oil dispersion) (13.21 mg, 0.330 mmol) is added under nitrogen to the solution of (E)-2-amino-7-(4-fluoro-2-pyridin-3-yl-phenyl)-4-methyl-7,8-dihydro-6H- quinazolin-5-one oxime (Intermediate 1) (0.1 g, 0.275 mmol) in anhydrous DMF (4 mL). After 5 min, N-Boc-4-(2-bromoethyl)piperazine (161 mg, 0.550 mmol) is added and the mixture is heated at 50°C for 1.5 h. The suspension is diluted with H20 and extracted with EtOAc. The organic phase is dried over Na2S04, filtered and concentrated under reduced pressure. The beige-orange residue is purified by flash column chromatography (eluent DCM/MeOH from 99/1 to 95/5) to give the expected compound (0.111 g, 0.193 mmol, Yield: 70percent). LC-MS: method A, rt=1.60 min; (ES+), M+H+= 576.5 1H-NMR (DMSO-d6) delta (ppm): 8.57 (dd, J=4.84, 1.61 Hz, 1 H); 8.53 (dd, J=2.2Q, 0.73 Hz, 1 H): 7.76 (ddd, J=7.92, 2.35, 1.76 Hz, 1 H); 7.66 (dd, J=8.80, 5.87 Hz, 1 H); 7.45 (ddd, J=7.78, 4.84, 0.88 Hz, 1 H); 7.31 (td, J=8.73, 2.79 Hz, 1 H); 7.1 1 (dd, J=9.68, 2.93 Hz, 1 H); 6.76 (s, 2 H); 4.15 (t, J=5.87 Hz, 2 H); 3.24-3.28 (m, 4 H); 2.94-3.08 (m, 2 H); 2.82-2.94 (m, 1 H); 2.54-2.66 (m, 4 H); 2.45 (s, 3 H); 2.32-2.39 (m, 4 H); 1.39 (s, 9 H)

As the paragraph descriping shows that 655225-01-7 is playing an increasingly important role.

Reference：
Patent; DAC SRL; AMICI, Raffaella; COLOMBO, Andrea; COURTNEY, Stephen Martin; MERCURIO, Ciro; MONTALBETTI, Christian Aldo Georges Napoleon; MORTONI, Annalisa; VARASI, Mario; WO2013/64919; (2013); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.,655225-01-7

Example 7Q ethyl (7R,20S)-16-{2-[4-(tert-butoxycarbonyl)piperazin-1-yl]ethyl}-18-chloro-1-(4-fluorophenyl)-19-methyl-15-oxo-10-{[2-(3,3,3-trifluoropropoxy)pyrimidin-4-yl]methoxy}-7,8,15,16-tetrahydro-14H-17,20-etheno-13,9-(metheno)-6-oxa-2-thia-3,5,16-triazacyclooctadeca[1,2,3-cd]indene-7-carboxylate A 4 mL vial equipped with stir bar and septum was charged with Example 7P (9.5 mg), tert-butyl 4-(2-bromomethyl)piperazine-1-carboxylate (6.8 mg) and cesium carbonate (11.3 mg). N,N-dimethylformamide (116 muL) was added, and the mixture was stirred at ambient temperature. After completion of the reaction as indicated by LC/MS (?30 minutes), the mixture was poured into water and extracted with three portions of ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. Purification by preparative thin-layer chromatography (0.5 mm thick, 20*20 cm, eluting with 100percent ethyl acetate) provided the title compound. LC/MS (APCI) m/z 1034.4 (M+H)+.

As the paragraph descriping shows that 655225-01-7 is playing an increasingly important role.

Reference：
Patent; AbbVie Inc.; AbbVie Deutschland GmbH & Co. KG; Brady, Patrick B.; Braje, Wilfried; Dai, Yujia; Doherty, George A.; Gong, Jane; Jantos, Katja; Ji, Cheng; Judd, Andrew S.; Kunzer, Aaron R.; Lai, Chunqiu; Mastracchio, Anthony; Risi, Roberto M.; Song, Xiaohong; Souers, Andrew J.; Sullivan, Gerard M.; Tao, Zhi-Fu; Teske, Jesse A.; Wang, Xilu; Wendt, Michael D.; Yu, Yiyun; Zhu, Guidong; Penning, Thomas D.; (218 pag.)US2019/55264; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

Step 1. 5-Bromo-4-(cyclobutylmethoxy)-1-methyl-3-(2-piperazin-1-ylethyl)-1,3-dihydro-2H-benzimidazol-2-one A solution of 5-bromo-4-(cyclobutylmethoxy)-1-methyl-1,3-dihydro-2H-benzimidazol-2-one (250 mg, 0.803 mmol) in N,N-dimethylformamide (7.96 mL) was treated with cesium carbonate (1.31 g, 4.02 mmol) followed by the addition of tert-butyl 4-(2-bromoethyl)piperazine-1-carboxylate (471 mg, 1.61 mmol), and the resultant reaction mixture was stirred at 60° C. overnight, after which time the LCMS analysis of the reaction mixture indicated complete conversion of the starting materials. The reaction mixture was diluted with ethyl acetate and water. Layers were separated and the organic layer was washed with brine, dried with magnesium sulfate, filtered, and concentrated in vacuo to give the crude intermediate tert-butyl carboxylate, which was used in further step without purification., 655225-01-7

The synthetic route of 655225-01-7 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; INCYTE CORPORATION; Yue, Eddy W.; Combs, Andrew P.; Douty, Brent; US2015/148342; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

655225-01-7, tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

655225-01-7, Example 1163 N-(imidazo[1,2-a]pyridin-7-ylmethyl)-5-[1-({4-methyl-1-[2-(piperazin-1-yl)ethyl]piperidin-4-yl}methyl)-1H-pyrazol-4-yl]thiophene-2-carboxamide (5912) A solution of N-(imidazo[1,2-a]pyridin-7-ylmethyl)-5-{1-[(4-methylpiperidin-4-yl)methyl]-1H-pyrazol-4-yl}thiophene-2-carboxamide (0.100 g, 0.197 mmol) in N,N-dimethylformamide (2 ml) was added tert-butyl 4-(2-bromoethyl)piperazine-1-carboxylate (0.058 g, 0.197 mmol) followed by N,N-diisopropylethylamine (0.138 ml, 0.788 mmol) and the reaction was stirred overnight. The reaction mixture was purified directly using normal phase chromatography and the resulting material was treated with HCl in dioxane (4M) for 2 hours then concentrated to give the title compound as a hydrochloride salt. 1H NMR (500 MHz, DMSO-d6) delta 14.64 (s, 1H), 10.40 (s, 1H), 9.72 (s, 1H), 9.54 (t, J=6.0 Hz, 1H), 8.89 (d, J=6.9 Hz, 1H), 8.34 (d, J=1.8 Hz, 1H), 8.22 (s, 1H), 8.16 (d, J=2.1 Hz, 1H), 7.91 (d, J=3.9 Hz, 1H), 7.87 (s, 1H), 7.83 (s, 1H), 7.50 (dd, J=7.0, 1.4 Hz, 1H), 7.28 (d, J=3.8 Hz, 1H), 4.64 (d, J=5.8 Hz, 2H), 4.23-3.54 (m, 10H), 3.35 (d, J=38.3 Hz, 8H), 1.72 (d, J=77.7 Hz, 4H), 0.98 (s, 3H); MS (ESI(+)) m/e 547 (M+H)+.

655225-01-7 tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate 15946441, apiperazines compound, is more and more widely used in various fields.

Reference：
Patent; AbbVie Inc.; Clark, Richard F.; Sorensen, Bryan; Osuma, Augustine T.; Frey, Robin; Longenecker, Kenton; Doherty, George; Curtin, Michael L.; Michaelides, Michael R.; Sweis, Ramzi F.; Pliushchev, Marina A.; Judd, Andy; Hansen, Todd M.; Heyman, Howard R.; US9187472; (2015); B2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.655225-01-7,tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

tert-Butyl 4-(2-((4-chloro-5-iodo-2-methoxyphenyl)amino)ethyl)piperazine-1-carboxylate To a stirred solution of 4-chloro-5-iodo-2-methoxyaniline (968 mg, 3.42 mmol) in anhydrous THF (20 mL) at 0¡ã C., NaH (60percent in mineral oil, 205.2 mg, 5.13 mmol) was added and the resulting mixture was stirred at reflux under nitrogen for 1 h. To this mixture, tert-butyl-4-(2-bromoethyl)piperazine-1-carboxylate (500 mg, 1.71 mmol) was added and the resulting mixture was stirred at room temperature for 15 h. The mixture was concentrated in vacuo and the residue was partitioned between ethyl acetate and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (10-30percent ethyl acetate/petroleum ether) to afford the desired product (180 mg, 21percent yield) as a solid., 655225-01-7

655225-01-7 tert-Butyl 4-(2-bromoethyl)piperazine-1-carboxylate 15946441, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; Ren, Pingda; Liu, Yi; Li, Liansheng; Feng, Jun; Wu, Tao; US2014/288045; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics